Investor Relations

Corporate Profile

We are a biopharmaceutical company focused on harnessing powerful biology underlying major diseases to develop transformative therapeutics for patients.

We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines.

We aspire to operate one of our industry’s most productive research and development engines and have built a robust pipeline of drug candidates – several of which are in clinical development – to address a spectrum of large, unmet medical needs. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. However, we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News and Events

Press Releases

  • 08/12/20

    NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results

    Read more
  • 07/31/20

    NGM Bio to Present at Two Upcoming Investor Conferences

    Read more
  • 07/27/20

    NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

    Read more

Events

  • More events are coming soon.

Stock Quote

Contact Information

Investor Relations:
ir@ngmbio.com

Media Relations:
media@ngmbio.com

Top